Live Breaking News & Updates on Induction Effects

Bristol Myers Squibb (NYSE:BMY) today announced that additional data from multiple studies evaluating
Zeposia (ozanimod) in ulcerative colitis (UC) were presented at Digestive Disease Week ® (DDW), taking place virtually May 21-23, 2021. These data deepen the understanding of
Zeposia and reinforce Bristol Myers Squibb’s commitment to understanding and addressing unmet needs in gastroenterology.
Research being shared includes:
Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis Over Time: Pooled Analysis from Phase 2, Phase 3, and Open-Label Extension Trials
Pooled analysis including data from the Phase 2 TOUCHSTONE study, Phase 3 True North study and open-label extension trial. Long-term treatment with ....

United States , Mary Beth Harler , Bristol Myers Squibb , American Society For Gastrointestinal Endoscopy , Bristol Myers Squibb Company , Health Economics , American Gastroenterological Association , Fibrosis Development , Society For Surgery Of The Alimentary Tract , Drug Administration , European Commission , Outcomes Research , Exchange Commission , European Medicines Agency , Myers Squibb , Digestive Disease Week , Severely Active Ulcerative Colitis Over Time , Pooled Analysis , Open Label Extension , Induction Effects , Clinical Symptoms , Inflammatory Biomarkers , Severely Active Ulcerative Colitis , Induction Phase , Free Remission , Severely Active Ulcerative Colitis Treated ,